Gastric and esophageal cancers: Guidelines updates

Crystal S. Denlinger*, Kristina A. Matkowskyj, Mary F. Mulcahy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

For the treatment of gastric and esophageal cancers, several pivotal trials - especially those evaluating immune checkpoint inhibitors (ICIs) - have altered the treatment landscape and led to changes in the NCCN Guidelines. In addition to pembrolizumab and nivolumab, new treatment options include trastuzumab-deruxtecan (T-DXd), ramucirumab, and trifluridine/tipiracil. These agents convey varying degrees of benefit depending on treatment line, PD-L1 expression, HER2 expression, and tumor histology. Recently, ICIs have been incorporated into the first-line treatment of HER2-negative advanced esophageal, gastroesophageal junction (GEJ), and gastric cancers, in addition to second-line treatment of advanced esophageal and GEJ cancer of squamous histology. T-DXd is another new second-line option for HER2-positive esophageal, GEJ, and gastric adenocarcino mas. ICIs are now moving into the adjuvant setting as well, and a new recommendation is nivolumab use after preoperative chemoradiation and surgery in patients who have residual disease identified at the time of their R0 resections.

Original languageEnglish (US)
Pages (from-to)639-643
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
DOIs
StatePublished - May 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Gastric and esophageal cancers: Guidelines updates'. Together they form a unique fingerprint.

Cite this